In terms of mechanism, treatment with a pan-PIM kinase inhibitor promoted increased ubiquitination and subsequent degradation of IKZF1 and IKZF3, two transcription factors crucial for the survival of myeloma cells. Here, IKZF1 is linked to plasma cell myeloma.